Spontaneous Bacterial Peritonitis - Prevention and Prophylaxis

Key Points

• SBP prophylaxis is not indicated for every patient with cirrhotic ascites.
• Give short-term antibiotic prophylaxis during acute upper GI bleeding in cirrhosis.
• Use long-term primary prophylaxis only in selected high-risk patients with advanced cirrhosis and low-protein ascites plus additional risk factors.
• Use secondary prophylaxis after a prior SBP episode because recurrence risk is high.
• Ciprofloxacin or TMP-SMX are common US oral regimens; norfloxacin is generally unavailable in the United States.
• Reassess long-term prophylaxis for resistance, C. difficile, adverse effects, and whether the indication persists.
• Breakthrough symptoms require diagnostic paracentesis even when the patient is taking prophylaxis.

Algorithm

1. Determine whether the patient has acute GI bleeding, a prior SBP episode, or high-risk low-protein ascites.
2. Confirm that prophylaxis criteria are met rather than prescribing for ascites alone.
3. Review allergies, renal function, prior cultures, QT risk, and local resistance.
4. Use ceftriaxone-based short-course prophylaxis during acute upper GI bleeding.
5. Use a guideline-supported oral regimen for appropriate primary or secondary long-term prophylaxis.
6. Reassess periodically for adverse effects and continued indication.
7. Perform prompt diagnostic paracentesis whenever breakthrough SBP is suspected.
8. Refer decompensated cirrhosis for transplant evaluation.

Clinical Synopsis & Reasoning

Spontaneous bacterial peritonitis is infection of ascitic fluid without a surgically treatable intra-abdominal source and has a high recurrence rate after a first episode. Prevention strategies are divided into short-term prophylaxis during acute upper GI bleeding, primary prophylaxis for selected high-risk patients who have never had SBP, and secondary prophylaxis after a documented SBP episode. These groups should not be conflated because the strength of indication and duration differ.

AASLD guidance supports antibiotic prophylaxis during upper GI bleeding in cirrhosis, typically with ceftriaxone for up to seven days. Long-term primary prophylaxis is generally reserved for advanced cirrhosis with low ascitic protein plus additional renal dysfunction, hyponatremia, or severe liver failure criteria. Secondary prophylaxis is commonly continued after an SBP episode because recurrence risk is high. A 2025 AASLD review also emphasizes increasing concerns about resistance, microbiome disruption, and uncertain mortality benefit in some primary-prophylaxis populations, so long-term antibiotics should not be prescribed to every patient with ascites.

Before starting chronic prophylaxis, confirm the indication, prior culture and resistance history, allergies, renal function, QT-prolonging medications, and local antimicrobial patterns. New abdominal pain, fever, encephalopathy, hypotension, AKI, or decompensation during prophylaxis still requires immediate diagnostic paracentesis because prophylaxis reduces risk but does not exclude breakthrough SBP.

Treatment Strategy & Disposition

For cirrhosis with acute upper GI bleeding, administer guideline-recommended short-course antibacterial prophylaxis, commonly ceftriaxone 1 g IV daily for up to seven days, adjusted for local resistance and clinical context. For long-term primary or secondary prevention in the United States, commonly used oral regimens include ciprofloxacin 500 mg daily or trimethoprim-sulfamethoxazole double strength daily. Norfloxacin is cited in guidelines but is generally unavailable in the United States.

Continue secondary prophylaxis while the patient remains at substantial recurrence risk, often until liver transplantation, death, or resolution of ascites and the relevant risk state. Primary prophylaxis should be reassessed periodically because antibiotic toxicity, resistant organisms, and C. difficile infection can outweigh benefit when the original high-risk criteria no longer apply or evidence is weak.

Prevention also depends on treating the cirrhosis itself. Evaluate for transplantation after decompensation, manage ascites appropriately, avoid unnecessary proton-pump inhibitors and nephrotoxins, and treat GI bleeding promptly. If a patient develops SBP despite prophylaxis, obtain ascitic and blood cultures and choose empiric therapy based on healthcare exposure, prior organisms, prophylactic drug, and local resistance rather than repeating the prophylactic agent.

Epidemiology / Risk Factors

• SBP is a common severe infection in decompensated cirrhosis with ascites.
• Recurrence after a first SBP episode is high without secondary prevention.
• Low ascitic protein has historically been used as a risk marker, but disease severity and renal dysfunction are also important.
• Antimicrobial resistance increasingly affects prophylaxis and breakthrough-infection management.

Investigations

Common Regimens

Pharmacology

Prognosis / Complications

• Preventing recurrent SBP can reduce episodes of infection and related decompensation.
• An SBP episode is a major prognostic event and should trigger liver-transplant evaluation.
• Breakthrough SBP on prophylaxis may involve resistant organisms and can be severe.
• Long-term outcome depends primarily on the severity of underlying cirrhosis and transplant candidacy.

Patient Education / Counseling

• Explain why long-term antibiotics are being used and that they do not guarantee protection from infection.
• Report fever, new abdominal pain, confusion, low blood pressure symptoms, or reduced urine output immediately.
• Review medication adverse effects and interactions at follow-up.
• Do not stop or substitute the prophylactic drug without discussing the plan with the liver team.
• Discuss transplant evaluation after SBP or other major decompensation.

Notes

This article is intentionally separate from the treatment article for active SBP. Prophylaxis is about risk selection and prevention, whereas active SBP requires immediate diagnostic paracentesis, therapeutic antibiotics, and albumin in selected patients.

Current AASLD educational review has renewed attention to the downside of indiscriminate long-term prophylaxis. The practical response is not to abandon prophylaxis, but to use it in the patients for whom guideline-supported risk is high and to reassess the indication over time.

References

1. AASLD: Ascites, SBP and HRS Practice Guidance — Link
2. AASLD: Antibiotics for SBP Prophylaxis, Why or Why Not? 2025 — Link